Company intelligence / Profile preview

Matisse Pharmaceuticals

Ownership
Private
Development stage
Other
01

Overview

Matisse Pharmaceuticals is developing M6229, a low-anticoagulant fraction of heparin that neutralizes toxic extracellular histones implicated in sepsis and septic shock. Preclinical studies have shown efficacy in animal models, and the drug is currently in phase 1/2a clinical development. The company recently completed a financing round to support a large-scale phase II trial and scale-up for commercial production. GMP manufacturing capabilities are operational for their lead compound.

Therapeutic areas
Infectious Diseases
Modalities
Small molecule (specifically, a non-anticoagulant heparin fraction)Biologic (heparin derivative)
Industry
Biotech
02

Drug pipeline

1 asset

isupartob sodium

1
03

Partnerships

No specific major pharmaceutical or biotech partnerships publicly disclosed; the company has built a network of strategic partners and investors.

Beyond the preview

Go deeper on Matisse Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matisse Pharmaceuticals.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call